Agenda
Subject to change. CLE panels are designated by an asterisk after the panel title.
Monday, Oct 27, 2025
8:30 AM ET
9:00 AM ET
Welcome to IPWatchdog’s Life Sciences Masters 2025
Renée C. Quinn
9:10 AM ET
The State of the Biopharma Industry: Significant Opportunity, Considerable Challenges *
This panel will lead off our Life Sciences Masters™ 2025 program. We will broadly discuss the state of the biopharmaceutical industry, what challenges the industry is facing, what opportunities exist, and what the panel expects for the remainder of 2025 and into 2026. Among other things, we will discuss (1) Trump Administration efforts to rely on Bayh-Dole march-in provisions to…
Becky Kaufman
Sherry Knowles
Gene Quinn
Robert Sahr
This panel will lead off our Life Sciences Masters™ 2025 program. We will broadly discuss the state of the biopharmaceutical industry, what challenges the industry is facing, what opportunities exist, and what the panel expects for the remainder of 2025 and into 2026. Among other things, we will discuss (1) Trump Administration efforts to rely on Bayh-Dole march-in provisions to…
,10:10 AM ET
10:30 AM ET
Biopharma Law & Policy Update: Legislation, Executive Action and Industry Impact *
The biopharmaceutical industry sits at the intersection of rapid scientific advancement and an increasingly complex legal and regulatory environment. This panel will dig into the latest developments in U.S. legislation, executive actions, and regulatory initiatives shaping the future of drug development, commercialization, and protection. Panelists will analyze how recent and pending actions in Congress and the White House could reshape…
Brent R. Bellows
Patrick Kilbride
Peter-Anthony Pappas
Gene Quinn
The biopharmaceutical industry sits at the intersection of rapid scientific advancement and an increasingly complex legal and regulatory environment. This panel will dig into the latest developments in U.S. legislation, executive actions, and regulatory initiatives shaping the future of drug development, commercialization, and protection. Panelists will analyze how recent and pending actions in Congress and the White House could reshape…
,11:30 AM ET
11:50 AM ET
The Truth About Pharma Patent Practices: Separating Fact and Fiction *
In the ongoing debate over prescription drug prices, the role of patents is often misunderstood—and sometimes deliberately misrepresented. This panel will present the perspective of brand-name pharmaceutical companies, exploring how patents support medical innovation, sustain research investment, and enable life-saving breakthroughs. Panelists will address the myths and misinformation spread by patent critics—including the repeated distortions from organizations like I-MAK—and will…
Christian Bauer
Paul Higgins
Emily Johnson
Joshua Kresh
Hon. Paul R. Michel
In the ongoing debate over prescription drug prices, the role of patents is often misunderstood—and sometimes deliberately misrepresented. This panel will present the perspective of brand-name pharmaceutical companies, exploring how patents support medical innovation, sustain research investment, and enable life-saving breakthroughs. Panelists will address the myths and misinformation spread by patent critics—including the repeated distortions from organizations like I-MAK—and will…
,1:50 PM ET
How Patents Drive Drug Development and Increase Patient Access *
Patent protections in the biopharmaceutical industry are designed to foster early innovation while ultimately enabling robust market competition—but the balance is often misunderstood. By granting innovators temporary market control over their discovery, patents encourage the investment needed for groundbreaking drug development. Once these protections expire, generic manufacturers can enter the market, which drives down prices, expands access, and fosters competitive…
Philip S. Johnson
Sherry Knowles
Justin Latona
Sarah Tully
Patent protections in the biopharmaceutical industry are designed to foster early innovation while ultimately enabling robust market competition—but the balance is often misunderstood. By granting innovators temporary market control over their discovery, patents encourage the investment needed for groundbreaking drug development. Once these protections expire, generic manufacturers can enter the market, which drives down prices, expands access, and fosters competitive…
,3:10 PM ET
The Price of Medicine: Why the U.S. Pays More for Prescription Drugs *
The cost of prescription pharmaceuticals is higher in the United States than anywhere else in the world, and many in the United States—including President Trump—are unhappy with this imbalance. But why do Americans pay more for prescription drugs? There are a variety of reasons why drugs cost more in the United States than in other countries, including the existence of…
Ratib Ali
Gabe McCool
Mark Merritt
Runa Shah-Qaderi
Teresa Summers
The cost of prescription pharmaceuticals is higher in the United States than anywhere else in the world, and many in the United States—including President Trump—are unhappy with this imbalance. But why do Americans pay more for prescription drugs? There are a variety of reasons why drugs cost more in the United States than in other countries, including the existence of…
,4:30 PM ET
How AI is Transforming Life Sciences: Balancing Innovation, IP and Data Risk
As artificial intelligence (AI) becomes integral to drug development, it brings both transformative opportunities and significant intellectual property (IP) risks, particularly in safeguarding confidential information and data. This panel will explore the cutting-edge uses of AI in the life sciences industry and how AI technologies intersect with intellectual property protections. This business-focused panel will explore key considerations for biopharma companies,…
Brian Cocca
Gary Lobel
Dhruv Sud
Giulia Toti
As artificial intelligence (AI) becomes integral to drug development, it brings both transformative opportunities and significant intellectual property (IP) risks, particularly in safeguarding confidential information and data. This panel will explore the cutting-edge uses of AI in the life sciences industry and how AI technologies intersect with intellectual property protections. This business-focused panel will explore key considerations for biopharma companies,…
,5:50 PM ET
Keynote: A Fireside Chat with Henry Hadad
We are pleased to have Henry Hadad, Senior Vice President and Deputy General Counsel for Bristol-Meyers Squibb, join us for a one-on-one conversation with Gene Quinn. SURVEY: https://www.surveymonkey.com/r/Keynote-A-Fireside-Chat-with-Henry-Hadad
Henry Hadad
Gene Quinn
We are pleased to have Henry Hadad, Senior Vice President and Deputy General Counsel for Bristol-Meyers Squibb, join us for a one-on-one conversation with Gene Quinn. SURVEY: https://www.surveymonkey.com/r/Keynote-A-Fireside-Chat-with-Henry-Hadad
,6:30 PM ET
Reception
Join us to network over beer, wine, cocktails and hors d’oeuvres.
Join us to network over beer, wine, cocktails and hors d’oeuvres.
,Tuesday, Oct 28, 2025
8:30 AM ET
9:00 AM ET
Welcome to Day 2 of IPWatchdog’s Life Sciences Masters 2025
Renée C. Quinn
9:10 AM ET
Global Considerations in Biopharma Patent Prosecution and Portfolio Development
Biopharmaceutical companies invest significantly in research and development (R&D) on a global scale, which leads to collaboration, partnerships and commercial opportunities that cross geographic boundaries. This international cooperation can often expedite drug discovery and development by combining resources, expertise, and capabilities, but it also comes with complexities, including those related to securing and defending patent rights across jurisdictions presents unique…
Axel B. Berger
Benjamin Heller
Colin Sandercock
Daniel Young
Biopharmaceutical companies invest significantly in research and development (R&D) on a global scale, which leads to collaboration, partnerships and commercial opportunities that cross geographic boundaries. This international cooperation can often expedite drug discovery and development by combining resources, expertise, and capabilities, but it also comes with complexities, including those related to securing and defending patent rights across jurisdictions presents unique…
,10:10 AM ET
10:30 AM ET
Developments and Trends for Biopharma Patents at the USPTO *
The biotechnology sector faces unique challenges in navigating the evolving patent landscape at the U.S. Patent and Trademark Office. This panel will explore recent developments in biotech patent examination, including subject matter eligibility, obviousness considerations, double patenting (particularly obviousness-type double patenting), and the different treatment between patent term adjustment (PTA) and patent term extension (PTE). Panelists will analyze recent case…
Anthony R. Prosser
Robert Sahr
Laura Smalley
The biotechnology sector faces unique challenges in navigating the evolving patent landscape at the U.S. Patent and Trademark Office. This panel will explore recent developments in biotech patent examination, including subject matter eligibility, obviousness considerations, double patenting (particularly obviousness-type double patenting), and the different treatment between patent term adjustment (PTA) and patent term extension (PTE). Panelists will analyze recent case…
,11:30 AM ET
11:50 AM ET
Enabling Biotech and Pharma Patents: Legal Challenges and Practical Solutions *
Biotechnology and pharmaceutical inventions often push the boundaries of what patent law requires in terms of written description and enablement. This panel will examine the evolving legal standards and recent case law that shape how applicants must describe and support their inventions to secure robust, enforceable patents. Panelists will discuss practical strategies for meeting disclosure requirements in complex fields such…
Sarah Fashena
Juliana Neves
John Rearick, Ph.D.
Charles Steenburg
Biotechnology and pharmaceutical inventions often push the boundaries of what patent law requires in terms of written description and enablement. This panel will examine the evolving legal standards and recent case law that shape how applicants must describe and support their inventions to secure robust, enforceable patents. Panelists will discuss practical strategies for meeting disclosure requirements in complex fields such…
,1:50 PM ET
Biologic Lifecycle Management: Optimizing Structures, Bioconjugates & Formulations
This panel will present a focused playbook for biopharma patent practitioners allowing them to protect the full scope of innovation reflected in the biologic development process. The discussion will explore how to identify patentable improvements in biologic structures, bioconjugates, and formulations, secure robust IP protection, and leverage regulatory incentives to maximize exclusivity. It will address legal, business, and policy considerations,…
Abi Heath
Marc Morley
Joshua Schoonover
This panel will present a focused playbook for biopharma patent practitioners allowing them to protect the full scope of innovation reflected in the biologic development process. The discussion will explore how to identify patentable improvements in biologic structures, bioconjugates, and formulations, secure robust IP protection, and leverage regulatory incentives to maximize exclusivity. It will address legal, business, and policy considerations,…
,3:10 PM ET
UPC Update: Liability Risks Before the UPC
The Unified Patent Court (UPC) is a hotbed for liability risks which require proper risk management. No question, injunctive relief is front and center in a system, which has for the time being established de facto an automatic injunction doctrine. However, many other liability risks are oftentimes equally important like the personal liability of directors, the obligation to recall infringing…
Gene Quinn
Tobias Wuttke
The Unified Patent Court (UPC) is a hotbed for liability risks which require proper risk management. No question, injunctive relief is front and center in a system, which has for the time being established de facto an automatic injunction doctrine. However, many other liability risks are oftentimes equally important like the personal liability of directors, the obligation to recall infringing…
,3:40 PM ET
Biopharma Patent Litigation Updates: Hatch-Waxman, BPCIA, and Beyond *
The pharmaceutical patent litigation landscape continues to evolve, with court decisions and regulatory actions shaping strategies for both brand and generic companies. This panel will provide an up-to-the-minute review of critical developments, including Orange Book disputes and Hatch-Waxman litigation for small molecules—highlighting cases including Teva v. Amneal and recent FTC enforcement trends. The panel will also compare and contrast Purple…
Shana Cyr
Heather Petruzzi
Gene Quinn
Sean Sheridan
The pharmaceutical patent litigation landscape continues to evolve, with court decisions and regulatory actions shaping strategies for both brand and generic companies. This panel will provide an up-to-the-minute review of critical developments, including Orange Book disputes and Hatch-Waxman litigation for small molecules—highlighting cases including Teva v. Amneal and recent FTC enforcement trends. The panel will also compare and contrast Purple…
,5:00 PM ET
In-House Counsel Perspective: Navigating Problems, Priorities & Pressures
OFF THE RECORD. This panel will be a frank conversation between senior level IP executives about what problems they are facing, what issues they are currently focusing on, and what keeps them awake at night. SURVEY: https://www.surveymonkey.com/r/In-House-Counsel-Perspective-Navigating-Problems-Priorities-and-Pressures
Heather Champion Brady
Kady Bruce
Colin Heitzmann
Cynthia Martin
Kwame Mensah
OFF THE RECORD. This panel will be a frank conversation between senior level IP executives about what problems they are facing, what issues they are currently focusing on, and what keeps them awake at night. SURVEY: https://www.surveymonkey.com/r/In-House-Counsel-Perspective-Navigating-Problems-Priorities-and-Pressures
,6:00 PM ET
Reception
Join us to network over beer, wine, cocktails and hors d’oeuvres.
Join us to network over beer, wine, cocktails and hors d’oeuvres.
,Wednesday, Oct 29, 2025
9:30 AM ET
IPWatchdog Unleashed Live Recording: Sherry Knowles
Join us in studio for a live recording of our weekly podcast IPWatchdog Unleashed. Our guest will be Sherry Knowles. Ms. Knowles is an intellectual property attorney with 30 years of experience in global corporate and private practice, and is a member of the inaugural class of the IPWatchdog Masters™ Hall of Fame. Currently the Principal of Knowles Intellectual Property Strategies,…
Sherry Knowles
Gene Quinn
Join us in studio for a live recording of our weekly podcast IPWatchdog Unleashed. Our guest will be Sherry Knowles. Ms. Knowles is an intellectual property attorney with 30 years of experience in global corporate and private practice, and is a member of the inaugural class of the IPWatchdog Masters™ Hall of Fame. Currently the Principal of Knowles Intellectual Property Strategies,…
,10:50 AM ET
IPWatchdog Unleashed Live Recording: Robert Sahr
Join us in studio for a live recording of our weekly podcast IPWatchdog Unleashed. Our guest is Robert Sahr, who is a Shareholder in the Biotechnology department of Wolf Greenfield Intellectual Property Law. Rob has worked extensively in technologies including antibodies, vaccines, chimeric antigen receptors, cell therapies, synthetic biology, medical devices, imaging agents, biologics and small molecules for new disease…
Robert Sahr
Gene Quinn
Join us in studio for a live recording of our weekly podcast IPWatchdog Unleashed. Our guest is Robert Sahr, who is a Shareholder in the Biotechnology department of Wolf Greenfield Intellectual Property Law. Rob has worked extensively in technologies including antibodies, vaccines, chimeric antigen receptors, cell therapies, synthetic biology, medical devices, imaging agents, biologics and small molecules for new disease…
,12:10 PM ET
IPWatchdog Unleashed Live Recording: TBA
Join us in studio for a live recording of our weekly podcast IPWatchdog Unleashed. Guest TBA.
Gene Quinn
Join us in studio for a live recording of our weekly podcast IPWatchdog Unleashed. Guest TBA.
,Sponsors
